Free Trial

Sera Prognostics Q3 2024 Earnings Report

Sera Prognostics logo
$4.12 -0.15 (-3.51%)
As of 02/21/2025 04:00 PM Eastern

Sera Prognostics EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.22
Beat/Miss
Missed by -$0.02
One Year Ago EPS
-$0.23

Sera Prognostics Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.09 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Sera Prognostics Earnings Headlines

Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
Sera Prognostics CFO sells $27,090 in stock
Sera Prognostics CEO sells $64,463 in stock
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA), a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

View Sera Prognostics Profile

More Earnings Resources from MarketBeat